The research, which appears in the Aug. 1 issue of the journal Cancer Research, is the team of 35 co-authors of the UCLA Jonsson Comprehensive Cancer Center with expertise in surgery, pathology, cancer biology, bioinformatics and diagnostic equipment.‘The scientific, medical and engineering have their own approach to solving problems,’ said Jing Sun, a postdoctoral researcher at CNSI and organic chemistry. ‘For the innovative process to produce something useful, it should be faster, better, cheaper and – of course, with the technology of micro small -.’
The ability to perform these measurements in vitro or molecular ‘fingerprints’, marks a new advance in molecular diagnostics that could ultimately help doctors predict patient prognosis and guide personalized treatment.
The researchers next applied the new platform for large cohorts of samples of cancer patients and to integrate the diagnostic approach in clinical trials of molecular therapies.
Researchers have also developed new bioinformatics – computational techniques and algorithms and statistical – that has allowed them to process and analyze data collected from single cell measurements MIC platform.
‘We are excited about the possibility of using this method to study the responses of individual tumors to therapeutic potential, and to improve our understanding of how to become resistant to treatment,’ said Harley Kornblum, a physician scientist who studies the biology of brain tumor and is a member of both the UCLA Center for Disability and intellectual research and cancer of the Johnson Center for Cell Biology Program Area.
Give the meat is a huge change difficult for the Americans, he said. A third of participants did not want to follow a vegetarian diet at the beginning of the study.
Molecular medicine and pharmacology graduate researcher Michael Masterman-Smith approached the project as a translational cancer biologist.
‘The MIC is essentially a cancer diagnostic chip that can generate a single cell’ molecular fingerprints ‘for a small amount of pathology samples, including brain tumor tissues,’ said Dr. Hsian-Rong Tseng, a UCLA associate professor molecular and medical pharmacology and a research leaders. ‘We are exploring the use of the MIC for generating informative molecular fingerprints from rare populations samples of Oncology -. For example, cancer stem cells’
CytoScale Diagnostics has signed a letter of agreement with the technology mentioned in this document.
Microscale technology platforms to find wide application in biological assays in which they are required careful handling and metering of limited sample, and the platform for the new MIC is able to make measurements on small samples provided by molecular tumor resection and biopsy using the fewest 1000-3000 cells, the researchers said.
‘The nature of the data cell of a brain tumor MIC has been exciting and challenging opportunity,’ said Dr. Nicholas Graham, a postdoctoral researcher at the CNSI who worked on data analysis. ‘To make sense of data, we had to develop new bioinformatics approaches that preserve the power of single cell analysis, but to allow a comparison of the patients.’
This study was funded by the National Cancer Institute / National Institutes of Health and the National Institute of Neurological Disorders and Disease .
‘The promise and the attractiveness of this approach is the small amount of tissue for analysis in the face of an increasing number of prognostic and predictive markers, and the ability to quantify the genetic heterogeneity of tumors,’ said Dr. William Yong, Jonsson Cancer Center physician-researcher who led the research aspects of the disease.
‘However, much work remains to validate this study with larger samples and with more points of reference.’